Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/28 cls
Allergy Therap (LSE:AGY) Jefferies Robin Campbell Downgrade Hold (from buy) 3% 61p
Campbell lowered his target to 65p from 200p, citing an "undeterminate delay" of FDA's clinical hold on clinical trials for AGY's Pollinex Quattro vaccines (see BioCentury, July 16).
Alnylam (ALNY) Banc of America Securities William Sargent Price target Buy -2% $32.77
Sargent raised his target to $38 from $30. He views the termination of a 2003 deal to develop RNAi therapeutics with Merck (MRK) as positive news for ALNY as it prevents knowledge sharing with a potential competitor. And he thinks MRK eventually will need to access ALNY's IP to develop any RNAi therapeutics, despite the pharma's acquisition of

Read the full 1240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers